Trial Profile
Randomized Adjuvant Phase III Trial of Six Cycles of Docetaxel+Hormonal Treatment Versus Hormonal Treatment in Patients With Intermediate or High-Risk Prostate Cancer Treated With Radical Radiotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms AdRad
- 24 Mar 2021 Planned End Date changed from 30 Aug 2020 to 30 Aug 2023.
- 24 Mar 2021 Planned primary completion date changed from 30 Aug 2020 to 30 Aug 2023.
- 15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium